Meaningful biomarkers in myeloproliferative neoplasms

During the MPN Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss meaningful biomarkers in myeloproliferative neoplasms. Benjamin Rolles delivered a presentation on potential biomarkers in MPN and the impact this may have on clinical practice and management strategies.
Benjamin Rolles opens by discussing the biomarkers associated with driving MPN, going on to highlight the need to better understand clonal hematopoiesis, particularly why certain healthy individuals within the population can harbor MPN driver gene mutations but not develop MPNs while others do. Rolles also covers high-risk constellations in MPN as well as biomarkers for disease monitoring.